Danaher Corporation (NYSE:DHR) Shares Sold by Zevin Asset Management LLC

Zevin Asset Management LLC cut its position in Danaher Corporation (NYSE:DHR - Free Report) by 5.1% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 60,219 shares of the conglomerate's stock after selling 3,216 shares during the period. Danaher accounts for 2.0% of Zevin Asset Management LLC's holdings, making the stock its 21st largest position. Zevin Asset Management LLC's holdings in Danaher were worth $12,345,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. GHP Investment Advisors Inc. increased its holdings in shares of Danaher by 396.0% in the 1st quarter. GHP Investment Advisors Inc. now owns 124 shares of the conglomerate's stock valued at $25,000 after acquiring an additional 99 shares during the last quarter. Heck Capital Advisors LLC purchased a new position in Danaher during the fourth quarter worth $27,000. Sierra Ocean LLC boosted its holdings in shares of Danaher by 116.9% during the first quarter. Sierra Ocean LLC now owns 141 shares of the conglomerate's stock worth $29,000 after purchasing an additional 76 shares during the last quarter. Smallwood Wealth Investment Management LLC acquired a new stake in shares of Danaher during the first quarter worth $31,000. Finally, Hurley Capital LLC acquired a new stake in shares of Danaher during the fourth quarter worth $34,000. Institutional investors and hedge funds own 79.05% of the company's stock.

Insider Buying and Selling at Danaher

In other news, Chairman Steven M. Rales sold 1,250,000 shares of the stock in a transaction on Monday, May 12th. The shares were sold at an average price of $196.74, for a total value of $245,925,000.00. Following the sale, the chairman owned 3,105,808 shares of the company's stock, valued at approximately $611,036,665.92. This represents a 28.70% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Christopher Paul Riley sold 15,805 shares of the firm's stock in a transaction dated Wednesday, April 30th. The shares were sold at an average price of $198.00, for a total transaction of $3,129,390.00. Following the completion of the sale, the executive vice president owned 15,179 shares in the company, valued at $3,005,442. This represents a 51.01% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 11.10% of the company's stock.

Danaher Stock Down 0.6%

NYSE:DHR traded down $1.06 during trading hours on Tuesday, reaching $187.02. The company had a trading volume of 3,822,609 shares, compared to its average volume of 3,535,108. The company has a quick ratio of 1.05, a current ratio of 1.43 and a debt-to-equity ratio of 0.31. The firm has a market cap of $133.84 billion, a price-to-earnings ratio of 36.29, a P/E/G ratio of 2.67 and a beta of 0.77. The business's 50-day simple moving average is $196.13 and its two-hundred day simple moving average is $204.86. Danaher Corporation has a twelve month low of $171.00 and a twelve month high of $281.70.

Danaher (NYSE:DHR - Get Free Report) last released its quarterly earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share for the quarter, beating analysts' consensus estimates of $1.64 by $0.16. Danaher had a net margin of 15.81% and a return on equity of 10.80%. The company had revenue of $5.94 billion for the quarter, compared to analyst estimates of $5.83 billion. During the same period last year, the firm earned $1.72 earnings per share. The firm's revenue was up 3.4% on a year-over-year basis. On average, equities analysts expect that Danaher Corporation will post 7.63 earnings per share for the current year.

Danaher Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, July 25th. Stockholders of record on Friday, June 27th will be paid a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.68%. Danaher's dividend payout ratio (DPR) is 24.85%.

Wall Street Analyst Weigh In

A number of research analysts have commented on DHR shares. Bank of America reduced their price objective on Danaher from $265.00 to $230.00 in a research note on Monday, April 14th. Jefferies Financial Group dropped their price target on Danaher from $260.00 to $230.00 and set a "buy" rating on the stock in a report on Tuesday, April 22nd. JPMorgan Chase & Co. cut their target price on shares of Danaher from $280.00 to $260.00 and set an "overweight" rating on the stock in a research note on Tuesday, April 22nd. Deutsche Bank Aktiengesellschaft cut their target price on shares of Danaher from $240.00 to $235.00 in a research note on Thursday, June 5th. Finally, The Goldman Sachs Group decreased their price objective on shares of Danaher from $260.00 to $240.00 and set a "neutral" rating for the company in a report on Wednesday, April 23rd. Three equities research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $248.48.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.